LUNG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pulmonx Corp (LUNG) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has taken steps to address past performance issues, its financials show declining revenue, net income, and EPS. The technical indicators are neutral, and there are no significant positive catalysts or trading signals to suggest immediate upside potential. A hold position is recommended until clearer signs of recovery or growth emerge.
The MACD is positive and expanding, indicating a slight bullish trend. RSI is neutral at 62.873, and moving averages are converging, suggesting no clear directional trend. Key support and resistance levels are Pivot: 1.405, R1: 1.545, S1: 1.266, R2: 1.631, S2: 1.18. Overall, the technical indicators are neutral.
Hedge funds have significantly increased their buying activity, with a 1169.71% increase over the last quarter. Gross margin improved by 4.86% YoY in Q4 2025.
No recent news or significant insider trading activity. Analyst price target was lowered from $6 to $5.
In Q4 2025, revenue dropped to $22.598 million (-4.91% YoY), net income dropped to -$10.425 million (-20.87% YoY), and EPS dropped to -0.25 (-24.24% YoY). Gross margin increased to 77.62% (+4.86% YoY), but overall financial performance remains weak.
Canaccord analyst William Plovanic lowered the price target to $5 from $6 but maintained a Buy rating, citing management's focus on addressing internal issues and returning to fundamentals.
